Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 1, 2007, Pages 109-116

  Jones, Ronald N ^a,b   Sader, Helio S ^a   Fritsche, Thomas R ^a   Pottumarthy, Sudha ^c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Human Services   (United States)

Author keywords

Cefepime; Ceftriaxone; Cephalosporins; North America; Pediatrics; SENTRY Program

Indexed keywords

AMPICILLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BLOOD FLOW; CHILD; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SENSITIVITY; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HUMAN; INFANT; KLEBSIELLA; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NORTH AMERICA; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; SENTINEL SURVEILLANCE;

EID: 33845448121     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.06.011     Document Type: Article

References (25)

1. Ambrose P.G., Owens R.C., Garvey M.J., and Jones R.N. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J. Antimicrob. Chemother. 49 (2002) 445-453
2. Albrich W.C., Monnet D.L., and Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg. Infect. Dis. 10 (2004) 514-517
3. Arrieta A.C., and Bradley J.S. Empiric use of cefepime in the treatment of serious urinary tract infections in children. Pediatr. Infect. Dis. J. 20 (2001) 350-355
4. Barradell L.B., and Bryson H.M. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 47 (1994) 471-505
5. Blumer J.L., Reed M.D., and Knupp C. Review of pharmacokinetics of cefepime in children. Pediatr. Infect. Dis. J. 20 (2001) 337-342
6. Bradley J. Introduction. The safety and efficacy of cefepime in pediatrics. Pediatr. Infect. Dis. J. 20 (2001) 329-330
7. Capparelli E., Hochwald C., Rasmussen M., Parham A., Bradley J., and Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob. Agents Chemother. 49 (2005) 2760-2766
8. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A7 (2006), NCCLS, Wayne, PA
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Document M100-S16 (2006), CLSI, Wayne, PA
10. Chuang Y.Y., Hung I.J., Yang C.P., Jiang T.H., Lin T.Y., and Huang Y.C. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr. Infect. Dis. J. 21 (2002) 203-209
11. Corapcioglu F., and Sarper N. Cefepime versus ceftazidime plus amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr. Hematol. Oncol. 22 (2005) 59-70
12. Elan Pharmaceuticals. Prescribing information for Maxipime® (2003), Elan Pharmaceuticals Inc., San Diego, CA. http://www.elan.com/Images/MAX0195_4PageMaxPI_tcm3-4348.pdf Available from, http://www.elan.com/Images/MAX0195_4PageMaxPI_tcm3-4348.pdf
13. Grassi G.G., and Grassi C. Cefepime: overview of activity in vitro and in vivo. J. Antimicrob. Chemother. 32 (1993) 87-94
14. Henry N.K., Hoecker J.L., and Rhodes K.H. Antimicrobial therapy for infants and children: guidelines for the inpatient and outpatient practice of pediatric infectious diseases. Mayo Clin. Proc. 75 (2000) 86-97
15. Jacobs M.R. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr. Infect. Dis. J. 22 (2003) S109-S119
16. Jones R.N., Biedenbach D.J., and Beach M.L. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 46 (2003) 77-80
17. Jones M.E., Karlowsky J.A., Draghi D.C., Thornsberry C., Sahm D.F., and Bradley J.S. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine and skin and soft tissue infections in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004) 445-455
18. Kaplan S.L., Mason Jr. E.O., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., Hoffman J.A., Givner L.B., Yogev R., and Barson W.J. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113 (2004) 443-449
19. Karlowsky J.A., Thornsberry C., Crtichley I.A., Jones M.E., Evangelista A.T., Noel G.J., and Sahm D.F. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob. Agents Chemother. (2003) 1790-1797
20. Kebudi R., Gorgun O., Ayan I., Gurler N., Akici F., and Toreci K. Randomised comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med. Pediatr. Oncol. 36 (2001) 434-441
21. Kessler R.E. Cefepime microbiologic profile and update. Pediatr. Infect. Dis. J. 20 (2001) 331-336
22. Kutluk T., Kurne O., Akyuz C., Ceyhan M., Kanra G., Buyukpamukcu M., and Secmeer G. Cefepime versus meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr. Blood Cancer 42 (2004) 284-286
23. Pong A.L., and Bradley J.S. Guidelines for the selection of antibacterial therapy in children. Pediatr. Clin. North Am. 52 (2005) 869-894
24. Saez-Llorens X., and O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr. Infect. Dis. J. 20 (2001) 356-361
25. Wong-Beringer A. Treating serious infections: focus on cefepime. Pharmacotherapy 24 (2004) 216S-223S